Technology | Implantable Cardioverter Defibrillator (ICD) | August 09, 2016

FDA Clears MRI-safe Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System

Approval grants MR-conditional labeling to all Emblem S-ICD systems, expands Boston Scientific’s ScienticImageReady portfolio

S-ICD, subcutaneous implantable cardioverter defibrillator, MRI safe ICD, Emblem
FDA Clears MRI-safe Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System

August 9, 2016 — The U.S. Food and Drug Administration (FDA) granted market approval for the Emblem MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling for all previously implanted Emblem S-ICD Systems. 

The new Emblem MRI S-ICD System is the latest addition to the Boston Scientific's growing line of ImageReady MR-conditional electrophysiology devices, which allow patients to undergo magnetic resonance imaging (MRI) safely.

The Emblem S-ICD system is a treatment option for patients at risk of sudden cardiac arrest, that leaves the heart and vasculature untouched, thus reducing the risk of complications associated with conventional transvenous ICD leads.

 

Watch the video, "How to Install a Subcutaneous ICD System." 
 

In addition to MR-conditional labeling, the device introduces two new features to the market – SMART Pass technology and Atrial Fibrillation (AF) Monitor. The SMART Pass technology, also being added to previously implanted Emblem S-ICD systems through a software update, increases the accuracy of the INSIGHT Algorithm to help ensure patients receive appropriate therapy from the device only when necessary. The AF Monitor feature is a detection tool designed to alert physicians after the identification of AF so they can make more informed treatment decisions for their patients.

Earlier this year, the company received FDA approval for the ImageReady MR-Conditional Pacing system, which includes Accolade MRI and Essentio MRI pacemakers, as well as Ingevity MRI pacing leads, designed to treat bradycardia. Patients implanted with the full system are able to receive full-body MR scans in a 1.5 Tesla environment when conditions of use are met. Additionally, the company is actively pursuing MRI compatibility for their currently approved implanted cardiac defibrillation and cardiac resynchronization therapy systems via the global ENABLE MRI study.

Boston Scientific received CE mark for the Emblem MRI S-ICD system earlier this year and began commercialization in Europe in June.

For more information: www.bostonscientific.com/sicd


Related Content

News | Atrial Fibrillation

September 14, 2022 — In recognition of Atrial Fibrillation (AFib) Awareness Month, Biosense Webster, Inc., part of ...

Home September 14, 2022
Home
News | Atrial Fibrillation

September 9, 2 022 — A large-scale international study led by Mount Sinai has yielded the first risk score that can help ...

Home September 09, 2022
Home
News | Atrial Fibrillation

August 31, 2022 — Science has long shown that men are at greater risk for developing atrial fibrillation (AFib) than ...

Home August 31, 2022
Home
News | Atrial Fibrillation

July 29, 2022 — A cohort study of persons with incident atrial fibrillation (AF) has found that AF after noncardiac ...

Home July 29, 2022
Home
News | Atrial Fibrillation

July 20, 2022 — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial ...

Home July 20, 2022
Home
News | Atrial Fibrillation

July 6, 2022 — Atrial fibrillation (AF) is a prevalent cardiovascular condition with one of the highest rates of ...

Home July 06, 2022
Home
News | Atrial Fibrillation

June 30, 2022 — A new onset of a rapid or irregular heartbeat that develops after surgery, often within a few days, is ...

Home June 30, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results of a new study reveal Black patients hospitalized with atrial fibrillation (AF) are under ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results from a new study show success of intended same day discharge (SDD) improves over time for ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the ...

Home May 17, 2022
Home
Subscribe Now